Drug · FAERS side-effect profile with label screen

Ambrosia Artemisiaefolia side effects: what 1,526 FDA adverse event reports show

Ambrosia Artemisiaefolia, Aralia Racemosa, Arnica Montana, Calendula Officinalis, Chromicum Acidum, Echinacea Purpurea, Eucalyptol, Kali Bichromicum, Kali Muriaticum, Kali Sulphuricum, Lac Vaccinum, Mercurius Iodatus Flavus, Mercurius Sulphuratus Ruber, Natrum Arsenicicum, Rosa Damascena, Sabadilla, Sanguinarinum Nitricum, Symphytum Officinale · 69 reaction terms · 634 drug–reaction co-reports · data 2026-09-14

Drug class

No validated FDA label found

closest label found was a multi-ingredient product (Ambrosia Artemisiaefolia, Aralia Racemosa, Arnica Montana, Calendula Officinalis, Chromicum Acidum, Echinacea Purpurea, ) and was not used

Who reports

1,526 reports · 55% serious · 37 with death outcome · 76% female

openFDA FAERS counts, all years, deduplication not applied

Used for

—

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 21 strongest signals

Reporting / coding artifact 4No label text to screen 17

What the badges mean

Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 48 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Impaired work ability	17	10.9 6.8–17.5ROR 11.0 · χ² 143 / p 3e-33	9.7 EB05 6.0 · IC025 +2.3 3/3 methods agree	No label text to screen	serious PRR 14.7	no trial data cached
Tendonitis	12	10.6 6.0–18.6ROR 10.7 · χ² 95 / p 9e-23	8.9 EB05 5.0 · IC025 +2.0 3/3 methods agree	No label text to screen	serious PRR 9.5	no trial data cached
Product substitution issue	43	10.3 7.7–13.8ROR 10.5 · χ² 351 / p 1e-78	9.8 EB05 7.5 · IC025 +2.7 3/3 methods agree	Reporting / coding artifact	serious PRR 12.3	no trial data cached
Quality of life decreased	10	10.2 5.5–19.0ROR 10.3 · χ² 74 / p 3e-18	8.1 EB05 4.3 · IC025 +1.8 3/3 methods agree	No label text to screen	serious PRR 8.0	no trial data cached
Muscle tightness	11	9.3 5.2–16.8ROR 9.4 · χ² 74 / p 4e-18	7.5 EB05 4.2 · IC025 +1.8 3/3 methods agree	No label text to screen	serious PRR 12.1	no trial data cached
Activities of daily living impaired	11	7.5 4.2–13.6ROR 7.6 · χ² 56 / p 4e-14	6.0 EB05 3.5 · IC025 +1.5 3/3 methods agree	No label text to screen	serious PRR 10.7	no trial data cached
Muscle twitching	12	7.1 4.1–12.5ROR 7.2 · χ² 57 / p 2e-14	5.8 EB05 3.5 · IC025 +1.5 3/3 methods agree	No label text to screen	serious PRR 9.8	no trial data cached
Musculoskeletal pain	23	6.0 4.0–9.0ROR 6.1 · χ² 91 / p 8e-22	5.4 EB05 3.8 · IC025 +1.7 3/3 methods agree	No label text to screen	serious PRR 6.1	no trial data cached
Movement disorder	14	6.0 3.5–10.0ROR 6.0 · χ² 53 / p 2e-13	5.1 EB05 3.2 · IC025 +1.4 3/3 methods agree	No label text to screen	serious PRR 5.7	no trial data cached
Emotional disorder	13	5.8 3.4–9.9ROR 5.8 · χ² 47 / p 4e-12	4.9 EB05 3.0 · IC025 +1.4 3/3 methods agree	No label text to screen	serious PRR 7.7	no trial data cached
Abasia	10	5.5 3.0–10.2ROR 5.5 · χ² 32 / p 6e-9	4.5 EB05 2.6 · IC025 +1.1 3/3 methods agree	No label text to screen	serious PRR 4.8	no trial data cached
Therapy cessation	17	4.6 2.9–7.3ROR 4.6 · χ² 44 / p 2e-11	4.1 EB05 2.7 · IC025 +1.2 3/3 methods agree	Reporting / coding artifact	serious PRR 8.3	no trial data cached
Nightmare	11	4.3 2.4–7.8ROR 4.4 · χ² 25 / p 3e-7	3.8 EB05 2.3 · IC025 +0.9 3/3 methods agree	No label text to screen	serious PRR 4.2	no trial data cached
Drug effect decreased	12	3.0 1.7–5.3ROR 3.0 · χ² 14 / p 8e-5	2.8 EB05 1.7 · IC025 +0.5	Reporting / coding artifact	serious PRR 3.6	no trial data cached
Injection site bruising	17	3.0 1.8–4.8ROR 3.0 · χ² 20 / p 3e-6	2.8 EB05 1.9 · IC025 +0.7	No label text to screen	serious PRR 2.2	no trial data cached
Injection site erythema (redness where injected)	24	2.7 1.8–4.0ROR 2.7 · χ² 24 / p 6e-7	2.6 EB05 1.8 · IC025 +0.7	No label text to screen	serious PRR 1.4 · 78% consumer	no trial data cached
Drug dose omission	31	2.5 1.8–3.6ROR 2.6 · χ² 28 / p 7e-8	2.5 EB05 1.8 · IC025 +0.7	Reporting / coding artifact	serious PRR 4.5	no trial data cached
Injection site swelling	14	2.5 1.5–4.3ROR 2.6 · χ² 12 / p 3e-4	2.4 EB05 1.5 · IC025 +0.4	No label text to screen	serious PRR 1.2	no trial data cached
Injection site pruritus	12	2.5 1.4–4.4ROR 2.5 · χ² 9 / p 0.001	2.3 EB05 1.4 · IC025 +0.2	No label text to screen	–	no trial data cached
Injection site pain (pain where injected)	51	2.3 1.8–3.0ROR 2.4 · χ² 37 / p 6e-10	2.3 EB05 1.8 · IC025 +0.7	No label text to screen	serious PRR 2.5 · 90% consumer	no trial data cached
Injection site reaction	10	2.0 1.1–3.7ROR 2.0 · χ² 4 / p 0.022	1.9 EB05 1.1 · IC025 -0.1 PRR-only: not supported by EBGM or IC	No label text to screen	serious PRR 2.2	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Injection site pain (pain where injected)	51	2.3 1.8–3.0ROR 2.4 · χ² 37 / p 6e-10	2.3 EB05 1.8 · IC025 +0.7	No label text to screen	serious PRR 2.5 · 90% consumer	no trial data cached
Product substitution issue	43	10.3 7.7–13.8ROR 10.5 · χ² 351 / p 1e-78	9.8 EB05 7.5 · IC025 +2.7 3/3 methods agree	Reporting / coding artifact	serious PRR 12.3	no trial data cached
Drug dose omission	31	2.5 1.8–3.6ROR 2.6 · χ² 28 / p 7e-8	2.5 EB05 1.8 · IC025 +0.7	Reporting / coding artifact	serious PRR 4.5	no trial data cached
Injection site erythema (redness where injected)	24	2.7 1.8–4.0ROR 2.7 · χ² 24 / p 6e-7	2.6 EB05 1.8 · IC025 +0.7	No label text to screen	serious PRR 1.4 · 78% consumer	no trial data cached
Musculoskeletal pain	23	6.0 4.0–9.0ROR 6.1 · χ² 91 / p 8e-22	5.4 EB05 3.8 · IC025 +1.7 3/3 methods agree	No label text to screen	serious PRR 6.1	no trial data cached
Injection site bruising	17	3.0 1.8–4.8ROR 3.0 · χ² 20 / p 3e-6	2.8 EB05 1.9 · IC025 +0.7	No label text to screen	serious PRR 2.2	no trial data cached
Therapy cessation	17	4.6 2.9–7.3ROR 4.6 · χ² 44 / p 2e-11	4.1 EB05 2.7 · IC025 +1.2 3/3 methods agree	Reporting / coding artifact	serious PRR 8.3	no trial data cached
Impaired work ability	17	10.9 6.8–17.5ROR 11.0 · χ² 143 / p 3e-33	9.7 EB05 6.0 · IC025 +2.3 3/3 methods agree	No label text to screen	serious PRR 14.7	no trial data cached
Injection site swelling	14	2.5 1.5–4.3ROR 2.6 · χ² 12 / p 3e-4	2.4 EB05 1.5 · IC025 +0.4	No label text to screen	serious PRR 1.2	no trial data cached
Movement disorder	14	6.0 3.5–10.0ROR 6.0 · χ² 53 / p 2e-13	5.1 EB05 3.2 · IC025 +1.4 3/3 methods agree	No label text to screen	serious PRR 5.7	no trial data cached
Emotional disorder	13	5.8 3.4–9.9ROR 5.8 · χ² 47 / p 4e-12	4.9 EB05 3.0 · IC025 +1.4 3/3 methods agree	No label text to screen	serious PRR 7.7	no trial data cached
Injection site pruritus	12	2.5 1.4–4.4ROR 2.5 · χ² 9 / p 0.001	2.3 EB05 1.4 · IC025 +0.2	No label text to screen	–	no trial data cached
Drug effect decreased	12	3.0 1.7–5.3ROR 3.0 · χ² 14 / p 8e-5	2.8 EB05 1.7 · IC025 +0.5	Reporting / coding artifact	serious PRR 3.6	no trial data cached
Muscle twitching	12	7.1 4.1–12.5ROR 7.2 · χ² 57 / p 2e-14	5.8 EB05 3.5 · IC025 +1.5 3/3 methods agree	No label text to screen	serious PRR 9.8	no trial data cached
Tendonitis	12	10.6 6.0–18.6ROR 10.7 · χ² 95 / p 9e-23	8.9 EB05 5.0 · IC025 +2.0 3/3 methods agree	No label text to screen	serious PRR 9.5	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Ambrosia Artemisiaefolia?

In FDA FAERS, the most frequently co-reported reaction terms for Ambrosia Artemisiaefolia are injection site pain, injection site erythema, musculoskeletal pain, injection site bruising, impaired work ability, injection site swelling. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Ambrosia Artemisiaefolia have an FDA boxed warning?

No validated FDA label could be retrieved for this product name, so this page cannot say.

Do FAERS signals prove that Ambrosia Artemisiaefolia causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

No FDA label passed the name-validation check for this product string, so label-based screening was skipped
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 69 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.